Founder Securities Co Ltd

Founder Securities released its 2026 interim report, with total operating revenue of 7.341 billion yuan and net profit attributable to the parent company of 2.957 billion yuan. Net cash inflow from operating activities was 3.266 billion yuan, ranking 28th among disclosed peer companies. The company's latest asset-liability ratio was 83.44%, up 0.76 percentage points from the previous quarter and up 2.88 percentage points from the same period last year. The latest ROE was 5.60%, and diluted earnings per share was 0.36 yuan. The number of shareholders was 200,400, and the top ten shareholders held 58.79% of the total share capital.

The 2026 National Essential Medicines List has been officially released. The number of proprietary Chinese medicines has expanded significantly to 318 varieties, with 65 newly added varieties achieving combined terminal sales of over 16 billion yuan at public medical institutions in 2025. For the first time, the new essential medicines list includes 16 clinically high-value innovative drugs in a batch, among which are four domestically developed Class I original new drugs. This marks a step forward for innovative drugs from medical insurance access to hospital deployment and grassroots availability. China Post Securities believes that the 986 deployment principle is expected to drive rapid volume growth for listed varieties, particularly benefiting traditional Chinese medicine enterprises that have already established channel advantages in grassroots markets. At the same time, innovative drug companies such as RemeGen, whose products have entered the basic medication list, are poised to open up broad space for long-term standardized treatment. Founder Securities pointed out that this round of adjustments has strengthened the investment themes of policy implementation, channel volume growth, and financial report penetration.